CTO-R5458-ONC-1826

Please Note: This trial is no longer enrolling new participants

A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma N;Richter J;Jagannath S;Lee HC;Hoffman JE;Suvannasankha A;Zonder JA;Shah MR;Lentzsch S;Baz R;Maly JJ;Namburi S;Pianko MJ;Ye JC;Wu KL;Silbermann R;Min CK;Vekemans MC;Munder M;Byun JM;Martínez-Lopez J;Cassady K;DeVeaux M;Chokshi D;Boyapati A;Hazra A;Yancopoulos GD;Sirulnik LA;Rodriguez Lorenc K;Kroog GS;Houvras Y;Dhodapkar MV;